Biogen sees negative Q2 impact from IPR&D, milestone expenses

5 hours ago 1

Biogen said it will incur a $46M charge in its Q2 results leading to a ($0.26) impact in its GAAP and non-GAAP EPS due to acquired in-process research and development (IPR&D), upfront, and milestone expenses.
The biotech said it began

Recommended For You